Last reviewed · How we verify
AbobotulinumtoxinA 300 UNT
AbobotulinumtoxinA 300 UNT, marketed by the University Foot and Ankle Foundation, is a therapeutic drug with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence, leveraging the patent protection to maintain exclusivity. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | AbobotulinumtoxinA 300 UNT |
|---|---|
| Sponsor | University Foot and Ankle Foundation |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Effects of Preoperative Botulinum Toxin A Injection on Respiratory System Function
- Evaluation of Intradetrusor AbobotulinumtoxinA and IncobotulinumtoxinA in Women With Overactive Bladder (PHASE4)
- Evaluating the Safety and Effect of abobotulinumtoxinA in the Gastrocnemius Muscle to Improve Equinus and Plantar Fasciitis Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AbobotulinumtoxinA 300 UNT CI brief — competitive landscape report
- AbobotulinumtoxinA 300 UNT updates RSS · CI watch RSS
- University Foot and Ankle Foundation portfolio CI